FibroBiologics, Inc. held its Annual Meeting of Stockholders on June 12, 2025. During the meeting, several proposals were presented and voted upon. Matthew Link and Victoria Niklas, M.D. were elected as Class II directors. The appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the year ending December 31, 2025, was ratified. An amendment to increase the authorized capital stock was approved. The issuance of shares of common stock to YA II PN, LTD., pursuant to the Standby Equity Purchase Agreement, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.